Business
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN, April 27, 2026--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy
About this update from Prothena Corporation Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/3b28ae38abe81d62685679a7e4e520fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ji6XgaipMn3aujKe4sYUYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwOA--/https://media.zenfs.com/en/business-wire.com/3b28ae38abe81d62685679a7e4e520fb","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fnkdbSUcDxgyEJ5NTpb0Fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA-/https://media.zenfs.com/en/business-wire.com/3b28ae38abe81d62685679a7e4e520fb","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3","length":125,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2029","length":165,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Fast Track Designation underscores the unmet need within ATTR-CM and could expedite the review of coramitug","length":111,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":401,"olType":false},{"type":"text","content":"DUBLIN, April 27, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter antibody currently in Phase 3 development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need.","length":523,"tagName":"p"},{"type":"text","content":""We are encouraged by Novo Nordisk’s receipt of Fast Track Designation for coramitug, which underscores their continued commitment to advancing coramitug for patients living with ATTR-CM," said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.","length":272,"tagName":"p"},{"type":"text","content":""We ar...